Willingness to pay for reduced incontinence symptoms
- PMID: 9352692
- DOI: 10.1046/j.1464-410x.1997.00420.x
Willingness to pay for reduced incontinence symptoms
Abstract
Objective: To measure the willingness to pay for a reduction in the number of micturitions and urinary leakages for patients with urge incontinence.
Patients and methods: A self-administered questionnaire with a binary willingness-to-pay question was administered to 541 patients in Sweden with urge or mixed incontinence; 461 questionnaires were returned. The reduction in micturitions and urinary leakages valued in the willingness-to-pay question was varied randomly between 25% and 50% in two different subsamples. Information was also collected about the number of micturitions and urinary leakage, health-related quality of life and socio-economic characteristics of the patients in the study.
Results: Quality of life was significantly related to the severity of the symptoms and was worse than that of the sex- and age-matched general Swedish population. The median (mean) willingness to pay per month was 240 (530) Swedish krona (SEK, 1 Pound = SEK 11.50) for a 25% reduction in micturitions and leakages and SEK 470 (1030) for a 50% reduction in micturitions and leakages. As hypothesized, the willingness to pay was significantly related to the size of the reduction in micturitions and leakages, the initial number of micturitions and leakages, and income.
Conclusions: Patients with incontinence problems are willing to pay substantial amounts for a reduction in the number of micturitions and leakages.
Similar articles
-
Urge incontinence. Quality of life and patients' valuation of symptom reduction.Pharmacoeconomics. 1998 Nov;14(5):531-9. doi: 10.2165/00019053-199814050-00005. Pharmacoeconomics. 1998. PMID: 10344916
-
Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema.Br J Dermatol. 1999 Dec;141(6):1067-75. doi: 10.1046/j.1365-2133.1999.03207.x. Br J Dermatol. 1999. PMID: 10606854
-
Economic considerations and outcome measurement in urge incontinence.Urology. 1997 Dec;50(6A Suppl):100-7; discussion 108-10. doi: 10.1016/s0090-4295(97)00602-x. Urology. 1997. PMID: 9426762
-
Willingness to pay for reductions in angina pectoris attacks.Med Decis Making. 1996 Jul-Sep;16(3):248-53. doi: 10.1177/0272989X9601600309. Med Decis Making. 1996. PMID: 8818123
-
Willingness to pay for antihypertensive therapy--further results.J Health Econ. 1993 Apr;12(1):95-108. doi: 10.1016/0167-6296(93)90042-d. J Health Econ. 1993. PMID: 10126492 Review.
Cited by
-
Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations.Pharmacoeconomics. 2005;23(10):995-1006. doi: 10.2165/00019053-200523100-00003. Pharmacoeconomics. 2005. PMID: 16235973 Review.
-
Evaluation and outcome measures in the treatment of female urinary stress incontinence: International Urogynecological Association (IUGA) guidelines for research and clinical practice.Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jan;19(1):5-33. doi: 10.1007/s00192-007-0495-5. Epub 2007 Nov 17. Int Urogynecol J Pelvic Floor Dysfunct. 2008. PMID: 18026681 Free PMC article. No abstract available.
-
Do women with overactive bladder have realistic expectations for therapy?Int Urogynecol J. 2010 Apr;21(4):409-14. doi: 10.1007/s00192-009-1049-9. Int Urogynecol J. 2010. PMID: 19936590
-
What's a 'cure'? Patient-centred outcomes of treatments for stress urinary incontinence.Int Urogynecol J Pelvic Floor Dysfunct. 2007 Jan;18(1):13-8. doi: 10.1007/s00192-006-0110-1. Epub 2006 Sep 12. Int Urogynecol J Pelvic Floor Dysfunct. 2007. PMID: 16967189 Review. No abstract available.
-
Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine.Drugs Aging. 2001;18(7):551-60. doi: 10.2165/00002512-200118070-00007. Drugs Aging. 2001. PMID: 11482747 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous